The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial.
 
Milind M. Javle
Other Relationship - Bayer; BeiGene; Incyte; Merck; Merck Serono; Novartis; Pieris Pharmaceuticals; QED Therapeutics; Rafael Pharmaceuticals; Seagen
 
Ivan Borbath
Consulting or Advisory Role - Novartis (Inst)
Research Funding - Celgene (Inst); Ipsen (Inst); Novartis (Inst)
 
Stephen John Clarke
Consulting or Advisory Role - AstraZeneca/MedImmune; AstraZeneca/MedImmune; Bayer; Ipsen; Merck
Speakers' Bureau - Merck; Novartis/Ipsen
 
Erika Hitre
No Relationships to Disclose
 
Christophe Louvet
Consulting or Advisory Role - Halozyme
Travel, Accommodations, Expenses - Roche
 
Teresa Macarulla Mercade
No Relationships to Disclose
 
Do-Youn Oh
Consulting or Advisory Role - ASLAN Pharmaceuticals; AstraZeneca; Bayer; Genentech/Roche; Merck Serono; Novartis; Taiho Pharmaceutical
Research Funding - Array BioPharma; AstraZeneca; Green Cross; Lilly; Novartis
 
Jennifer L. Spratlin
Honoraria - Celgene; Lilly/ImClone; Sanofi
Consulting or Advisory Role - Astellas Pharma; Celgene; Lilly/ImClone; Sanofi; Taiho Pharmaceutical
Research Funding - Sanofi
Travel, Accommodations, Expenses - Astellas Pharma
 
Juan W. Valle
Honoraria - Ipsen
Consulting or Advisory Role - Agios; AstraZeneca; Delcath Systems; Genoscience Pharma; Incyte; Ipsen; Keocyt; Merck; Mundipharma; Novartis; PCI Biotech; Pfizer; Pieris Pharmaceuticals; QED Therapeutics
Speakers' Bureau - Imaging Equipment Limited; Ipsen; Novartis; Nucana
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Celgene; Nucana
 
Karl Heinz Weiss
Consulting or Advisory Role - Alexion Pharmaceuticals; Bayer; Bristol-Myers Squibb; Chiesi; Eisai; GMP-Orphan; Novartis; Univar; Vivet Therapeutics; Wilson Therapeutics
Speakers' Bureau - Alexion Pharmaceuticals; Bristol-Myers Squibb; Falk Pharma; GMP-Orphan; Ipsen; Univar
Research Funding - Alexion Pharmaceuticals (Inst); Eisai (Inst); GMP-Orphan (Inst); Novartis (Inst); Univar (Inst); Wilson Therapeutics (Inst)
Travel, Accommodations, Expenses - Gilead Sciences
 
Craig Berman
Employment - QED Therapeutics
 
Michael Howland
Employment - QED Therapeutics
 
Yining Ye
Employment - QED Therapeutics
 
Terry Cho
Employment - QED Therapeutics
 
Susan Moran
Employment - QED Therapeutics
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - 3DMedcare; Agios; Alignmed; Amgen; Antengene; Aptus Clinical; ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BiolineRx (I); Boston Scientific; BridgeBio Pharma; Bristol-Myers Squibb; CARsgen Therapeutics; CASI Pharmaceuticals; Celgene; Celsion; Cipla; CytomX Therapeutics (I); Daiichi Sankyo; Debiopharm Group; Delcath Systems; Eisai; EMD Serono (I); Exelixis; Genoscience Pharma; Gilead Sciences (I); Halozyme; Halozyme; Hengrui Pharmaceutical; Inovio Pharmaceuticals; Ipsen; Janssen (I); Jazz Pharmaceuticals; Kyowa Hakko Kirin; LAM Therapeutics; Lilly; Loxo (I); Medimmune; Merck Serono; Minapharma; Newlink Genetics (I); Novella Clinical; Onxeo; PCI Biotech; PCI Biotech; Pfizer (I); Pharmacyclics (I); Pharmacyte Biotech (I); Pieris Pharmaceuticals (I); QED Therapeutics; RedHill Biopharma; Roche; Sanofi; SERVIER; Silenseed (I); Sillajen; Sirtex Medical; Sirtex Medical; SOBI (I); Targovax (I); Tekmira; Tekmira; twoXAR; Vicus Therapeutics (I); Yakult Pharmaceutical; Yakult Pharmaceutical; Yiviva
Research Funding - Acta Biologica (Inst); Agios (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Celgene (Inst); Exelixis (Inst); Genentech (Inst); Halozyme (Inst); Incyte (Inst); Lilly (Inst); MabVax (Inst); MedImmune (Inst); Momenta Pharmaceuticals (Inst); Novartis (Inst); OncoMed (Inst); OncoQuest (Inst); Polaris (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Polaris